Diabetes Ther. 2021 Mar;12(3):897-911. doi: 10.1007/s13300-021-01017-x. Epub 2021 Feb 17.

Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Yoshio Nagai, Kiyoyasu Kazumori, Tomomi Takeshima, Kosuke Iwasaki, Yasushi Tanaka

PMID: 33598855 PMCID: PMC7947126 DOI: 10.1007/s13300-021-01017-x

Abstract

INTRODUCTION: Metformin has dose-dependent hypoglycemic effects on patients with type 2 diabetes (T2D). In Japan, metformin has been prescribed at lower doses than in Western countries. We analyzed the effect of increasing the metformin dose on glycemic control and compared it to a combination therapy with dipeptidyl peptidase-4 inhibitors (DPP-4i) and a replacement therapy with DPP-4i.

METHODS: This is a cohort study using a Japanese claims database. Patients with T2D who had been initially treated with low-dose metformin (≥ 500 mg/day and < 1000 mg/day) and then given a prescription change by increasing metformin to a higher dose (≥ 1000 mg/day) (increased-dose), adding DPP-4i (drug-added), or switching to DPP-4i (drug-switched) were included in this study. The primary outcome was the change in HbA1c levels at 12 months from the baseline period.

RESULTS: Among 2,726,437 patients with T2D, 494 were included. Of these patients, 226, 240, and 28 patients were classified as increased-dose, drug-added, and drug-switched groups, respectively. The HbA1c levels at 12 months from the index significantly decreased compared to that during the baseline period. The change was the highest in the drug-added group (- 1.06%), followed by the increased-dose (- 0.91%) and the drug-switched groups (- 0.37%). Among the subset of patients who did not receive any antidiabetic drugs other than metformin or DPP-4i, the highest change in HbA1c levels was observed in the increased-dose group (- 0.84%), followed by the drug-added (- 0.67%) and the drug-switched (- 0.42%) groups. The order of decrease from baseline remained the same for all the study groups after the propensity score weighting adjustment.

CONCLUSION: The effect on glycemic control when increasing the metformin dose was studied in patients who had been receiving low-dose metformin. Increasing metformin dosage shows effectiveness and could be one of the next treatment options in patients who were prescribed low-dose metformin as the first-line treatment.

Keywords: Claims database; Combination drug therapy; Dipeptidyl peptidase-4 inhibitors; Dose increased; Drug switch; Glycated hemoglobin A; Glycemic control; Hypoglycemic agents; Metformin; Type 2 diabetes

References

1. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491–7. - PubMed
2. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7:28–39. - PubMed
3. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669–701. - PubMed
4. Odawara M, Kawamori R, Tajima N, et al. Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2017;8:286–95. - PubMed
5. Kameda T, Kumamaru H, Nishimura S, Kohsaka S, Miyata H. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators. Curr Med Res Opin. 2020;36:749–56. - PubMed
6. Tamura Y, Kato H, Hiroi S, et al. A study on the prescription status of metformin and DPP-4 inhibitors in patients with type 2 diabetes mellitus in Japan: an analysis data from health insurance administrative claims. Ther Res. 2017;38:1231–7. - PubMed
7. The Japan Diabetes Society. Clinical practice guideline for diabetes 2019. Tokyo: Nankodo Co., Ltd.; 2019. - PubMed
8. Nishimura R, Kato H, Kisanuki K, et al. Effectiveness of a dipeptidyl peptidase-4 inhibitor as add-on therapy to metformin and of dose-escalation of metformin in Japanese patients with type 2 diabetets mellitus in real-world clinical practice settings: a retrospective analysis of a medical information database. Ther Res. 2018;39:325–36. - PubMed
9. Nishimura R, Kato H, Kisanuki K, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9:e025806. - PubMed
10. Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14:927–36. - PubMed
11. Odawara M, Hamada I, Suzuki M. Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus. Diabetes Ther. 2014;5:169–81. - PubMed
12. Kaku K, Sumino S, Katou M, Nishiyama Y, Kinugawa Y. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:463–7. - PubMed
13. Odawara M, Yoshiki M, Sano M, Hamada I, Lukashevich V, Kothny W. Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Ther. 2015;6:17–27. - PubMed
14. Suzuki K, Yoshioka T, Wakui Y. Quantifying the effect of metformin 1000 mg/day in Japanese patients with type 2 diabetes. Int J Clin Med. 2014;05:894–901. - PubMed
15. Suzuki K, Mitsuma Y, Anraku T, Kitagawa M, Hasegawa K, Hatta M. A study on efficacy and safety of increasing metformin from 1000 to 1500 mg/day in Japanese patients with type 2 diabetes mellitus. Prog Med. 2017;37:237–43. - PubMed
16. Takahashi H, Nishimura R, Tsujino D, Utsunomiya K. Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study. J Diabetes Investig. 2019;10:714–22. - PubMed
17. Ishii M. DRG/PPS and DPC/PDPS as prospective payment systems. Jpn Med Assoc J. 2012;55:279–91. - PubMed
18. Ministry of Health, Labor and Welfare. [Statistical classification of diseases and cause of death 2013] (Internet). http://www.mhlw.go.jp/toukei/sippei/ . Accessed Nov, 24 2020. - PubMed
19. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75. - PubMed
20. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65:20–9. - PubMed
21. Salvatore T, Pafundi PC, Marfella R, et al. Metformin lactic acidosis: should we still be afraid? Diabetes Res Clin Pract. 2019;157:107879. - PubMed
22. Chang CH, Sakaguchi M, Dolin P. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. Pharmacoepidemiol Drug Saf. 2016;25:1196–203. - PubMed

Publication Types

• Journal Article